Leerink Partners Maintains Multiple Buy Ratings on Biotech Stocks Amid Growth Optimism

Leerink Partners has maintained positive ratings across several biopharma and healthcare stocks, highlighting growth potential and clinical progress. For IDEXX Laboratories, the firm reiterated an Outperform rating with a $580 price target, emphasizing the promising launch of the InVue Dx diagnostic console expected to drive recurring revenue growth in 2026 and beyond. aTyr Pharma also received an Outperform rating with a $16 target, supported by optimism about its upcoming Phase 3 trial results for efzofitimod in pulmonary sarcoidosis, despite inherent trial risks. Disc Medicine was reaffirmed as a Buy with an $85 price target, driven by positive data from its hematology-focused pipeline and anticipated accelerated approval for bitopertin. Ardelyx Inc. received a Buy rating with a $10 target due to solid commercial execution and a strong cash position, despite some recent market challenges. Meanwhile, Walgreens Boots Alliance was rated Hold with an $11.50 target, with growth in pharmacy operations offset by front-store retail challenges and increased investments, alongside its pending acquisition by Sycamore Partners.